培美曲塞联合铂类方案三线治疗晚期非小细胞肺癌的临床疗效及疾病预后

Effect of Pemetrexed Combined with Platinum in Third-line Treatment of Advanced Non-small Cell Lung Cancer and Prognosis Analysis

目的探讨培美曲塞联合铂类方案三线治疗晚期非小细胞肺癌(NSCLC)的临床疗效以及疾病预后。方法选取60例晚期非小细胞肺癌患者,采用回顾性分析的方法,把入选病例分为观察组和对照组,每组30例。对照组采用培美曲塞单药治疗,观察组采用培美曲塞联合铂类方案治疗。比较2组患者的肿瘤治疗效果、预后情况以及毒副作用。结果观察组的总有效率为66.67%(20/30),对照组为36.67%(11/30),差异有统计学意义(P<0.05);观察组的疾病控制率为90.00%(27/30),对照组为63.33%(19/30),差异有统计学意义(P<0.05)。观察组患者的PFS(19.21±1.32)较对照组高(15.21±1.32)(P<0.05)。观察组患者的OS(32.21±1.32)较对照组高(26.21±1.32)(P<0.05)。观察组患者的生活质量评分(QOL)(84.21±1.34)较对照组高(63.21±1.62)(P<0.05)。观察组总不良反应发生率低于对照组(10.00%<36.67%),差异有统计学意义(P<0.05)。结论培美曲塞联合铂类方案三线治疗NSCLC的疗效较好,可延长患者生存时间,降低不良反应,值得进一步临床研究探讨。

Objective To investigate the effect of pemetrexed combined with platinum in third-line treatment of advanced non-small cell lung cancer（ NSCLC） and prognosis analysis. Methods 60 cases of NSCLC were analyzed,and divided into the observation group（ 30 cases） and the control group（ 30 cases） using digital random grouping method. The observation group was treated with pemetrexed combined with platinum. The control group was treated with pemetrexed. After treatment,clinical efficacy,survival and toxicity were compared in the 2 groups. Results The total effective rate in the observation group was66. 67%（ 20/30） and the total effective rate in the control group was 36. 67%（ 11/30）. There were significant differences in the total effective rate between the 2 groups（ P〈0. 05）. The disease control rate in the observation group was 90. 00%（ 27/30） and the disease control rate in the control group was 63. 33%（ 19/30）. There were significant differences in the disease control rate between the 2 groups（ P〈0. 05）. FPS（ 19. 21 ± 1. 32） in the observation group was higher than FPS（ 15. 21 ± 1. 32） in the control group（ P〈0. 05）. OS（ 32. 21 ± 1. 32） in the observation group was higher than OS（ 26. 21 ± 1. 32） in the control group（ P〈0. 05）. QOL（ 84. 21 ± 1. 34） in the observation group was higher than the control group（ 63. 21 ± 1. 62）（ P〈0. 05）. The rate of adverse reactions in the observation group was higher than the control group（ 10. 00% 〈36. 67%）（ P〈0. 05）. Conclusion Pemetrexed combined with platinum in the treatment of NSCLC can effectively improve the clinical symptoms and prognosis,reduce the rate of adverse reactions,which is worthy of further clinical research.